-+ 0.00%
-+ 0.00%
-+ 0.00%

Autonomix Medical Presents Data Showing 66% Pain Reduction at Three Months in Pancreatic Cancer Study

PUBT·11/20/2026 13:29:01
Listen to the news
Autonomix Medical Presents Data Showing 66% Pain Reduction at Three Months in Pancreatic Cancer Study
  • Autonomix Medical reported approximately $8.6 million cash as of November 20, 2026, funding operations into, but not beyond, Q3 2027.
  • The company targets FDA De Novo approval in 2028 for pancreatic cancer-related pain.
  • Its initial proof-of-concept study showed a 65.6% pain-score reduction at three months among six responding patients assessed.
  • All seven responders assessed for opioid use at three months required no opioids.
  • A follow-on, 20-subject study evaluates its sensing and ablation catheters, expanding into additional visceral cancers and earlier-stage pancreatic cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief on November 20, 2026, and is solely responsible for the information contained therein.